Avid Bioservices Inc (CDMO)

[hopefilled2014]

For your reading pleasure and w/o any curve balls from an honest long:

"Here's what I see (re: Avid):

In Avid I see a fast growing state of the art biopharmaceutical manufacturing facility, capable of producing some of the most sophisticated substances in the pharma world. I see an expanding facility capacity that can now produce many millions of dollars of third party products for its contracted customers. I also see a forecast of doubling and more of that revenue through the expanding facilities.

I think, most importantly, we see an FDA approved facility capable of producing in house MAbs like Bavituximab and Betabodies. This manufacturing capability and, especially capacity, is an FDA requirement for launching a commercially FDA approved biologic like Bavi. We have to realize that when Avid, wholly owned by Peregrine, manufactures Bavituximab for commercial treatment of cancers, we are talking about a much higher valuation for Peregrine itself. Bavi is likely to cost patients or their insurers, something in the order of $100,000 to $120,000 per full course treatment. This is an Avid valuation upgrade for those not satisfied with a measly $40,000,000 and growing annual revenue stream, because major product will be TALCEPTRX.

Peregrine has recently obtained a Trade Mark, TALCEPTRX, for the commercial use of Bavituximab. To maintain this Trade Mark, Peregrine needs to have TALCEPTRX (Bavi) on the market within a 6-month window. According to CP, who found this "ihub PR", Peregrine was pursuing this trade mark name even after they stopped SUNRISE, so they have reason to believe that Bavi will be FDA approved in the near term.

I think that Bavi, in the SUNRISE P3 NSCLC trial performed as was expected, and that Peregrine ran the SUNRISE P3 trial with an intent to obtain FDA approval. Peregrine had a depth of double blind Bavi/Doce data for its FDA presentation study, and thereby knew that they would need the trade mark, TALCEPTRX.

I have also seen the recent NCCN document that states the existence of two planned I-O trials. One is with AstraZeneca combihttp://www.garmanbuilders.com/ning Bavi with Durvalumab in NSCLC, and a second trial combining Bavi with Merck's Keytruda for treating liver cancer. This is another example of something we would not have seen yet if it were not for the document being made available here on ihub by?? I don't know who originally provided this to the board.

Peregrine, through TexSW, has human I-O data for Bavi plus Yervoy. According to the ASCO 2016 abstract, Peregrine has human dosing data on Bavi combined with Durvalumab. This too has yet to be PR'd in data form, but may be being shared at negotiating tables, of which we are also not privy to at this point.

So, in short, Avid is worth a heck of a lot more than its 3rd party production evaluation.

Peregrine has a trade mark TALCEPTRX that is already into a 6-month (must use commercially) window.

Peregrine has reasons to want this trade mark in place in the near term.

Peregrine has a body of Double Blind data from 2nd line NSCLC clinical trials.

Peregrine has human cancer data of Bavi in I-O combinations.

Bavi is involved with an AZN I-O combination trial, and in another combination I-O trial with Merck's Keytruda.

IMO" Sunstar